Therefore, RCC can evade p53-dependent apoptosis by TGase 2 expression, which is induced by treatment with an anti-cancer drug such as doxorubicin.28 RCC may take advantage of the fact that TGase 2 destabilizes p53 activation induced by doxorubicin. This evidence concerns the gene TP53 and renal cell carcinoma.